The purpose of this study is determine if dararumumab enhances the effectiveness of revlimid in patients with smoldering myeloma. You must be diagnosed with asymptomatic high risk smoldering multiple myeloma.
Contact phone
Carolyn Krahulik | 517.364.2811
Contact email
cancerclinicaltrials@sparrow.org
Principal investigator
Dr. Gordan Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Smoldering Myeloma
Webform